Innavac Pty Ltd is a biotechnology company spun out of the University of Melbourne that is developing novel, synthetic Toll-like receptor (TLR) agonists as vaccine adjuvants and for the prevention and treatment of respiratory infections.  It is based on research by Professor David Jackson and his team at the Department of Immunology / Peter Doherty Institute for Infection and Immunity.